The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Lilly O.; Merck Serono; MSD; Pierre Fabre; Roche; SERVIER
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Pharmaceutical; Incyte; Lilly O.; Merck Serono; MSD; SERVIER
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo Pharmaceutical (Inst); Hutchison China Meditech (Inst); Incyte (Inst); Merck Serono (Inst); Mirati Therapeutics (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst); SERVIER (Inst)
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.
 
Kanwal Pratap Singh Raghav
Honoraria - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Consulting or Advisory Role - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Research Funding - Abbvie (Inst); Abbvie (Inst); Bayer (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Guardant Health (Inst); HiberCell (Inst); Innovent Biologics (Inst); Janssen (Inst); Merck Serono (Inst); Roche/Genentech (Inst); UCB (Inst); Xencor (Inst)
 
Salvatore Siena
Stock and Other Ownership Interests - Guardant Health; Myriad Genetics
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; CheckmAb; Clovis Oncology; Daiichi Sankyo; Incyte; Merck; Novartis; Roche/Genentech; Seagen
Research Funding - MSD Oncology (Inst)
Patents, Royalties, Other Intellectual Property - Amgen
Travel, Accommodations, Expenses - Amgen; Bayer; Roche
 
Atsuo Takashima
Honoraria - Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Eisai (Inst); Merck Sharp & Dohme (Inst); Ono Pharmaceutical (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Takeshi Kato
Honoraria - Asahi Kasei; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Takeda
Research Funding - Chugai Pharma
 
Marc Van Den Eynde
Consulting or Advisory Role - amgen (Inst); Bayer (Inst); BMS (Inst); Lilly (Inst); Merck KGaA (Inst); MSD (Inst); Pierre Fabre (Inst); SERVIER (Inst)
Research Funding - Merck KGaA (Inst)
Travel, Accommodations, Expenses - Amgen (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Servier (Inst); Servier (Inst)
 
Maria Di Bartolomeo
Honoraria - BMSi; Lilly; MSD Oncology; SERVIER
Consulting or Advisory Role - Lilly; MSD Oncology
Research Funding - Lilly (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca
 
Yoshito Komatsu
No Relationships to Disclose
 
Hisato Kawakami
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo; Lilly Japan; Merck Serono; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo Co. Ltd.,; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kobayashi Pharmaceutical (Inst)
 
Marc Peeters
Leadership - Qurin
Stock and Other Ownership Interests - BIMINI BioTech
Honoraria - Amgen; Bayer; BMS; Merck; MSD; Roche; Sanofi; SERVIER; Sirtex Medical
Consulting or Advisory Role - Amgen; Bayer; Ipsen; Merck; MSD; Qurin; Remedus; Sanofi; Sirtex Medical; TERUMO
Speakers' Bureau - Amgen; Bayer; Merck Serono; Roche; Sanofi; SERVIER; Sirtex Medical
Research Funding - Amgen; Bayer; Ipsen; Novartis; Roche
 
Thierry Andre
Honoraria - AMGEN; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Merck Serono; Merck Serono; Pierre Fabre; Roche/Genentech; Sanofi; Seagen; SERVIER; Ventana Medical Systems
Consulting or Advisory Role - Amgen; Aptitude Health; Astellas Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; GamaMabs Pharma; Gilead Sciences; GlaxoSmithKline; Gritstone Bio; Kaleido Biosciences; MSD Oncology; Nordic Bioscience; Pierre Fabre; Seagen; SERVIER; Tesaro; Transgene
Travel, Accommodations, Expenses - MSD Oncology; MSD Oncology
(OPTIONAL) Uncompensated Relationships - Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group; ARCAD Foundation; ARCAD Foundation; Gercor
 
Sara Lonardi
No Relationships to Disclose
 
Kensei Yamaguchi
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Jeanne Tie
Honoraria - Amgen; Merck Serono; MSD Oncology; Pierre Fabre; SERVIER; SERVIER
Consulting or Advisory Role - Bristol-Myers Squibb; Haystack Oncology; MSD Oncology; Novartis
Travel, Accommodations, Expenses - Roche
 
Cristina Gravalos Castro
Honoraria - Amgen; Daichi (Inst); Incyte; Merck; Pfizer (Inst); SERVIER; Servier (Inst)
Consulting or Advisory Role - Amgen
Travel, Accommodations, Expenses - Merck
 
John H Strickler
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Beigene; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Inivata; Lilly; Natera (Inst); Pfizer; Pionyr; Roche/Genentech; Seagen; Silverback Therapeutics; Takeda; Viatris; Zentalis
Research Funding - A*STAR (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene; Curegenix (Inst); Daiichi Sankyo/Lilly; Erasca, Inc (Inst); Leap Therapeutics (Inst); Lilly (Inst); Nektar (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silverback Therapeutics (Inst)
Travel, Accommodations, Expenses - Seagen
 
Daniel Barrios
Employment - Daiichi Sankyo Inc.
 
Qi Yan
Employment - Astellas Pharma; Daiichi Sankyo
Stock and Other Ownership Interests - daiichi sankyo
 
Takahiro Kamio
Employment - Daiichi Sankyo/Astra Zeneca
 
Kojiro Kobayashi
Employment - DAIICHI SANKYO CO., LTD.
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Merck; MSD K.K.; Ono Pharmaceutical
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Genomedia (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst)